Microfluidic “Pouch” Chips for Immunoassays and Nucleic Acid Amplification Tests

Mauk, Michael G.; Liu, Changchun; Qiu, Xianbo; Chen, Dafeng; Song, Jinzhao; Bau, Haim H.

doi:10.1007/978-1-4939-6911-1_30

Cited by 5 publications

(6 citation statements)

References 33 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alongside geographical information, this will be the future diagnostics armaments researchers should be looking forward to developing. Microfluidic integrated cassettes ("chips") for processing samples and analysis to facilitate point-ofcare (POC) immunoassays and nucleic acid-based amplification tests have been shown as innovative approaches [284,285].…”

Section: Next-generation Monitoring Toolsmentioning

confidence: 99%

“…The microfluidic device, with the integrated RNA isolation (influenza virus clinical specimens) approach via microfluidic oilwater interfaces, has recently been employed as a point of use (POU) tool for diagnostics [287]. There are many versions of such microfluidic cassettes or chips (acrylic and polycarbonate) for nucleic acid-based tests or immunoassays with suitable fabrication techniques allowing the storage of reagents, fluid actuation, and flowing control [284]. Integrating the isothermal LAMP amplification reaction with the microfluidic chip using small volumes, i.e., 1 μL reaction volume for each assay, and measuring fluorescence intensity using a smartphone is not only an economical but also a time-saving option [275] compared to available commercial kits for SARS-CoV-2 to assess viral load in sewage samples.…”

Section: Next-generation Monitoring Toolsmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Crisis Creates Opportunity towards Global Monitoring & Surveillance

et al. 2021

View full text Add to dashboard Cite

The spectrum of emerging new diseases as well as re-emerging old diseases is broadening as infectious agents evolve, adapt, and spread at enormous speeds in response to changing ecosystems. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recent phenomenon and may take a while to understand its transmission routes from less traveled territories, ranging from fomite exposure routes to wastewater transmission. The critical challenge is how to negotiate with such catastrophic pandemics in high-income countries (HICs ~20% of the global population) and low-and middle-income countries (LMICs ~ 80% of the global population) with a total global population size of approximately eight billion, where practical mass testing and tracing is only a remote possibility, particularly in low-and middle-income countries (LMICs). Keeping in mind the population distribution disparities of high-income countries (HICs) and LMICs and urbanisation trends over recent years, traditional wastewater-based surveillance such as that used to combat polio may help in addressing this challenge. The COVID-19 era differs from any previous pandemics or global health challenges in the sense that there is a great deal of curiosity within the global community to find out everything about this virus, ranging from diagnostics, potential vaccines/therapeutics, and possible routes of transmission. In this regard, the fact that the gut is the common niche for both poliovirus and SARS-CoV-2, and due to the shedding of the virus through faecal material into sewerage systems, the need for long-term wastewater surveillance and developing early warning systems for better preparedness at local and global levels is increasingly apparent. This paper aims to provide an insight into the ongoing COVID-19 crisis, how it can be managed, and what measures are required to deal with a current global international public health concern. Additionally, it shed light on the importance of using wastewater surveillance strategy as an early warning practical tool suitable for massive passive screening, as well as the urgent need for microfluidic technology as a rapid and cost-effective approach tracking SARS-CoV-2 in wastewater.

show abstract

Section: Next-generation Monitoring Toolsmentioning

confidence: 99%

Section: Next-generation Monitoring Toolsmentioning

confidence: 99%

COVID-19 Crisis Creates Opportunity towards Global Monitoring & Surveillance

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Encapsulation of reagents in natural polysaccharide was also developed to store chemicals on chips . Storage of reagents in a liquid form, which was a challenge until now, was performed using micro pouches or bioinert glass ampoules.…”

Section: Integrationmentioning

confidence: 99%

Innovative technologies for point‐of‐care testing of viral hepatitis in low‐resource and decentralized settings

Duchesne

Lacombe

2017

Journal of Viral Hepatitis

View full text Add to dashboard Cite

According to the Global Burden of Diseases, chronic viral hepatitis B and C are one of the most challenging global health conditions that rank among the first causes of morbidity and mortality worldwide. Low- and middle-income countries are particularly affected by the health burden associated with HBV or HCV infection. One major gap in efficiently addressing the issue of viral hepatitis is universal screening. However, the costs and chronic lack of human resources for using traditional screening strategies based on serology and molecular biology preclude any scaling-up. Point-of-care tests have been deemed a powerful potential solution to fill the current diagnostics gap in low-resource and decentralized settings. Despite high interest resulting from their development in recent years, very few point-of-care devices have reached the market. Scaling down and automating all testing steps in 1 single device (eg, sample preparation, detection and readout) is indeed challenging. But innovations in multiple disciplines such as nanotechnologies, microfluidics, biosensors and synthetic biology have led to the creation of chip-sized laboratory systems called "lab-on-a-chip" devices. This review aims to explain how these innovations can overcome technological barriers that usually arise for each testing step while developing integrated point-of-care tests. Point-of-care test prototypes rarely meet the requirements for mass production, which also hinders their large-scale production. In addition to logistical hurdles, legal and economic constraints specific to the commercialization of in vitro diagnostics, which have also participated in the low transfer of innovative point-of-care tests to the field, are discussed.

show abstract

“…Pouch chips are an attractive design option for autonomous microfluidic devices, providing a means for fluid storage (reservoirs), fluid actuation (pumping), and flow control (valving) [7][8][9][10]. By attaching or laminating flexible polymer sheet materials (e.g.…”

Section: Introductionmentioning

confidence: 99%

“…Flexible sheet can also be used to realize diaphragm valves that constrict flow in channels or seal chambers for processing. Chip design, materials, fabrication, and accompanying instrumentation and actuators are presented in detail [8][9][10].…”

Section: Introductionmentioning

confidence: 99%